3. Outdated Algorithms

The visiting room at Victorville Correctional Facility was designed to prevent intimacy. Plastic chairs bolted to the floor, a table too narrow to pass anything across, fluorescent lights that rendered every face pale and guilty. Eleanor Mercier sat on one side of the table. Adrian Voss sat on the other. Between them, a pane of scratched Plexiglas that made his features slightly distorted, as if he were already underwater.

She had not told her supervisor about this visit. Officially, she was following up on a routine evidentiary lead in the opioid case. Unofficially, she was testing a hypothesis she could not yet articulate.

"Dr. Voss," she said. "My name is Special Agent Mercier, FBI. I'd like to ask you some questions."

Voss looked at her with an expression that was neither hostile nor welcoming. He had the eyes of a man who had learned to measure people quickly, the way a chemist measures reagents: what are you, and what will you do when mixed with me?

"You're the first federal agent who's actually come here," he said. "I've written six letters. Did you read them?"

"I haven't read your letters. I'm here about something else." She paused, watching his reaction. "I'm investigating irregularities in clinical trial reporting by Kaelstrom Biopharma. Your name appeared in some old personnel records. I'm hoping you can provide context."

It was a lie, carefully constructed. She had read his letters—she had requested copies from the Bureau's mail processing unit two days ago—but she did not want him to know that yet. She wanted to see what he would volunteer, and what he would hold back.

Voss leaned forward slightly. "Context," he repeated. "That's a careful word. What kind of irregularities?"

"Procedural. Documentation gaps. Nothing I can discuss in detail." She opened a notebook, more for the appearance of formality than for any need to record. "You worked on a compound called CX-903. Can you describe your role in that project?"

For the next twenty minutes, Voss talked. He described the molecular structure of CX-903 with the precision of a man who had built it atom by atom. He explained the potassium channel modulation, the metabolic pathway, the liver enzyme interactions. He spoke in the flat, unemotional tone of a scientist presenting data. Mercier took notes, but she was not really listening to the pharmacology. She was listening to the man.

His story was coherent. That was the first thing she noticed. Liars tended to over-explain, to add unnecessary details, to anticipate objections before they were raised. Voss did none of that. He simply described what he had done and what he had discovered, as if he were reciting a paper he had memorized long ago.

"When you reported your safety concerns," Mercier said, "what happened?"

"I was called into a meeting with the vice president of regulatory affairs. His name was Leland Bryce."

Mercier's pen stopped. "Bryce?"

"Yes. Dr. Leland Bryce. He was the company's liaison with the FDA. He also had privileges at several nursing homes in the state. I didn't know that at the time. I learned it later, after I was already inside."

Mercier felt the pieces shift. Leland Bryce was the attending physician who had signed all thirteen death certificates at Larkspur Rest. He was not just a company executive. He was the man who had been present at every death, who had written "cardiac arrest" in careful block letters on each certificate, who had ordered that no autopsies be performed because the cause of death was "apparent."

"Bryce is still with Kaelstrom?"

"He was promoted. Chief Medical Officer now. He testifies before Congress about drug pricing." Voss's voice was dry, but something flickered behind his eyes. "I read about it in the newspaper. They send us the newspaper here, three days late."

Mercier closed her notebook. The Plexiglas between them suddenly felt thinner.

"Dr. Voss, I'm going to ask you a direct question. Do you have any evidence—physical evidence—that CX-903 was administered to patients at Larkspur Rest?"

Voss was silent for a long moment. "There's a backup server at a facility in Durham, North Carolina. It contains raw data sets from the original CX-903 trials, including patient-level data that was never submitted to the FDA. The data shows enrollment numbers that exceed the official count by approximately forty subjects. Those forty subjects, I believe, were the Larkspur residents."

"Where is this server?"

"In a storage room in the basement of Kaelstrom's Durham research center. It was decommissioned five years ago, but the drives were never wiped. I have the access password."

Mercier felt her pulse quicken. "Who gave you that password?"

"A man named Martin Shore. He was a biostatistician on the CX-903 project. He died three days ago."

"Convenient."

"Not for him." Voss's voice was flat. "Glioblastoma. He knew he was dying when he wrote to me. He wanted to clear his conscience before the end."

Mercier studied his face through the scratched plastic. She had interviewed hundreds of people in her career—witnesses, suspects, informants, liars of every variety. She had developed an instinct for deception that she trusted more than any formal training. And everything about Adrian Voss told her he was telling the truth.

But instinct was not evidence. A dead man's letter was not admissible. A password to a server that might or might not exist was not probable cause. And even if the server existed, even if the data was there, she would need a warrant to search it—a warrant that required a judge to find probable cause based on the word of a convicted felon and a coroner's marginalia.

"What do you want?" she asked.

Voss looked at her as if the question were absurd. "I want someone to look at the data. I want someone to count the bodies. I want someone to ask why thirteen people died of the same thing in the same place at the same time and no one thought it was strange."

"That's not a legal remedy."

"No," Voss said. "It's a human one."

The conversation ended shortly after that. Mercier walked out of the visiting room into the cold December air. The prison parking lot was nearly empty, the asphalt cracked and patched. She sat in her car for a long time, the engine idling, the heater blowing tepid air against her face.

She had a choice. She could file her preliminary inquiry and wait for the Bureau's legal team to determine whether there was sufficient predicate to open a formal investigation. That process could take months. During those months, the Durham server might be wiped, the tissue samples might be destroyed, and Leland Bryce might retire to a country where extradition was difficult. Or she could do something faster.

She pulled out her phone and called Henderson, the county coroner.

"The tissue samples from Larkspur," she said. "Can you send them to the FBI lab in Quantico?"

"I'd need a chain-of-custody request. Takes about two weeks."

"Do it. Mark it urgent."

She hung up and scrolled through her contacts until she found the name of a federal magistrate judge she had appeared before in a previous case. Judge Elaine Morrison was known for being thorough, skeptical, and willing to sign warrants at unusual hours. Mercier composed a detailed affidavit, outlining everything she had: the coroner's notes, the statistical anomaly, Voss's testimony, the withdrawn IND for CX-903, the subsequent filing for Avantix, the presence of Leland Bryce at every death. She did not mention Martin Shore's letter—it was hearsay, and it would weaken the application. She stuck to what could be verified.

She sent the affidavit at nine-fifteen in the evening. At eleven-thirty, Judge Morrison signed the warrant. Mercier called the FBI field office in Raleigh and requested a team to execute the search of the Durham facility the following morning.

Then she drove home, took a shower, and tried to sleep. She could not.

At six o'clock the next morning, the phone rang. It was the special agent in charge of the Raleigh field office. His voice was tight.

"We executed the warrant at the Durham facility an hour ago," he said. "The storage room was empty. The server racks had been removed. According to the facility manager, they were decommissioned and sent to an electronics recycling center four days ago."

Mercier closed her eyes. "Four days."

"The recycling center processes materials within forty-eight hours. The drives are shredded. There's nothing left to search."

She thanked him and hung up. Four days. Martin Shore had died three days ago. The day before his death, someone had ordered the destruction of the server. The timeline was too precise to be coincidence. Someone inside Kaelstrom had known exactly when to move.

She sat on the edge of her bed and stared at the wall. The server was gone. The tissue samples were still in transit to Quantico, but even if they showed traces of CX-903, the chain of custody was vulnerable—the samples had been sitting in a county storage unit for years. A competent defense attorney would tear them apart.

She had one card left to play. She had not told Voss about the warrant, or the search, or the destruction of the server. And she had not told anyone at Kaelstrom that she had visited him. As far as the company knew, the FBI was investigating a procedural matter, and the server had been destroyed before it could become evidence.

But there was another server. There had to be. Kaelstrom would not have gone to the trouble of silencing Voss, monitoring Martin Shore, and destroying the Durham backup unless there was something else they were protecting. The CX-903 trial data was dangerous, but the real threat was the connection to Avantix—the new drug that was on track for FDA approval. If Avantix had been developed using data from illegal human trials, the liability would be measured in billions of dollars. And the people who made decisions about billions of dollars did not leave their fate to a single backup server in a basement.

She opened her laptop and began searching for any connection between Kaelstrom's data infrastructure and the nursing home chain that owned Larkspur Rest. The chain was called Evergreen Senior Living, a privately held company with thirty-seven facilities across six states. Its corporate filings were sparse, but one detail stood out: the company's chief financial officer, a woman named Margaret Cho, had previously worked at Kaelstrom Biopharma as a director of clinical operations. She had left Kaelstrom six months before the first Larkspur death. She had joined Evergreen three months after that.

Mercier stared at the screen. The pieces were no longer just beginning to look like a picture. They were beginning to look like a conspiracy.

She picked up the phone and called the prison at Victorville. She needed to speak to Voss again. But this time, she was not going to ask him for information. She was going to ask him for help.